Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) shares saw an uptick in trading volume on Monday . 1,504 shares changed hands during mid-day trading, an increase of 115% from the previous session’s volume of 701 shares.The stock last traded at $10.25 and had previously closed at $10.31.

Bavarian Nordic Price Performance

The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of 6.64 and a beta of 1.34. The business’s 50-day moving average price is $9.90 and its 200 day moving average price is $10.97.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings results on Friday, November 14th. The company reported $0.72 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The firm had revenue of $281.11 million for the quarter. As a group, sell-side analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.